

Candidate development of PD-L1xIL-2v immuno-ONCOLOGY (MB201) applying a novel bispecific antibody platform technology

MustBio Inc.



ONCOLOGY	Candidate
Product Type	Immunoglobulin Product (Bispecific Antibody)
Indication	1st indication: NSCLC, Breast Cancer, Melanoma 2nd indication: Colorectal Cancer, Renal Cancer, Gastric Cancer
Target	Programmed Death-Ligand 1 [PD-L1] and Interleukin-2 [IL-2]
MoA (Mechanism of Action)	<p>MB201 inhibits PD-L1 and selectively activates the effector T cells, simultaneously. Therefore, MB201 can maximize an anti-tumor effect by tumor-directed immune activation without peripheral toxicity.</p> <div style="display: flex; justify-content: space-around; align-items: flex-start;"> <div style="text-align: center;"> <p><u>mAb / Combination</u></p> <p>Systemic immuno-activation</p> </div> <div style="text-align: center;"> <p><u>PD-L1/IL-2v BsAb</u></p> <p>Tumor directed immuno-activation</p> </div> <div style="text-align: center;"> <p>CD8 T cell Treg cell</p> </div> </div>
Competitiveness	<ol style="list-style-type: none"> 1. Patented multi-specific Ab platform technology 2. CD8+ T cell-selective IL-2v 3. Superb safety profile and excellent anti-tumor efficacy
Development Stage	Candidate
Route of Administration	Parenteral-intravenous